• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Equine recurrent uveitis (Proceedings)

August 1, 2011
Susan Keil, DVM, MS, DACVO

Herpes virus keratitis

Herpes virus keratitis

     • Prevalence:

          o EHV-2 has a high overall seropositive rate (90%) that does not have a defined correlation with clinical disease

          o Affects foals and adults

     • Clinical Appearance:

          o Variable pain, blepharospasm, epiphora, edema, vascularization

          o Common: classic appearance of multiple multifocal opacities which may be rose bengal positive (superficial erosion) or fluorescein stain positive (superficial ulcer); does not have to have stain retention

          o EHV-1 manifestations (blindness, optic neuritis, strabismus) distinctly different

     • DDX:

          o Influenced by region

          o Immune-mediated - Midwest

          o Early fungal – primary differential for many

          o Other ulcerative – traumatic, foreign body, KCS

          o Non-ulcerative keratitis – immune-mediated keratitis, corneal degeneration, calcific band keratopathy

          o Conformation difficult – high seropositive in normal population

          o Primarily – Rule out diagnosis combined with positive response to tx

          o Electron microscopy, virus isolation,

     • Pathogenesis:

          o EHV-2 is a gamma herpesvirus producing lifelong infections characterized by variable periods of disease recrudescence and latency.

          o Reactivation associated with stress (shipping, training, breeding)

          o Latency established in lymphocytes and trigeminal and ciliary ganglia

     • TX:

          o Anti-viral efficacy for equine EHV-2 have not been tested in vivo or in vitro

          o Anti-viral medications considered virostatic and must be administered at high frequency (4-6 times daily)

          o Topical NSAID

          o Topical prophylactic antibacterial

          o Systemic NSAID

          o Lysine – 10-30 grams orally once daily

          o Topical cycloplegic – mydriatic for reflex keratouveitis

          o Topical steroid?

     • Prognosis: Variable, often taking time and patience

Bacterial ulcerative keratitis

     • Prevalence:

          o Frequent problem

          o Streptococcus, Staphlococcus, Pseudomonas sp.

          o Numerous others also reported including anaerobic (clostridium sp)

          o Mixed infections, evolving infections common

     • Clinical Appearance:

          o Non-specific: blepharoedema, pain, epiphora, mucopurulent discharge, corneal opacification

          o Specific: stromal involvement will produce cellular infiltration, marked edema, and deepening of the ulcer bed +/- keratomalacia ("melting")

          o Anterior uveitis: often severe (hypotony, miosis, flare, hypopyon, synechia)

          o Corneal neovascularization

          o Vision reduction / loss

     • DDX:

          o Infectious ulcerative keratitis (fungal, viral)

          o Traumatic / foreign body

          o Non-infectious ulcerative keratitis (superficial, eosinophilic,

          o Non-ulcerative conditions (stromal abscess, immune-mediated keratitis)

          o **Perform cytology and bacterial culture / sensitivity

     • Pathogenesis:

          o Loss of the epithelial barrier allows pathogenic and non-pathogenic bacteria to invade the stroma

               • Protease production by bacteria, epithelial cells, inflammatory cells, and stromal fibroblasts results in extensive keratomalacia

               • MMP-2,MMP-9, neutrophil elastase

     • Medical TX:

          o Control inflammation, control infection, control pain, decrease proteolysis

          o Placement of subpalpebral lavage system

          o Topical antibiotic selection based on culture; administered q 2-6 hours

               • Gram Negative – aminoglycosides, chloramphenicol (not for Pseudomonas sp.), ciprofloxacin, ofloxacin, neomycin / polymyxin B

               • Gram Positive - chloramphenicol, mofloxacin, neomycin, bacitracin

          o Topical mydriatic – cycloplegic (1% atropine)

               • Reduces risk of posterior synechia and secondary glaucoma

               • Degree of mydriasis correlates with degreed of cycloplegia

                    √ More severe reflex keratouveitis requires more frequent tx

          o Systemic NSAIDs –

               • Flunixin meglumine (1.1 mg / kg) PO or IV q 12 hrs

               • Taper dose with control of disease

Advertisement

                    √ Often tapered too soon

          o Systemic steroids – not preferred due to increased risk

          o Omeprazole (Gastrogard) –

               • preventative dose = 2 mg/kg PO qd

               • treatment dose = 4 mg/kg PO qd

          o Topical antiproteases – Used to control upregulated protease activity

               • Autologus serum: serine protease entrapment

               • EDTA 0.2%: calcium / zinc chelation of MMPs

               • Tetracyclines: Ca / Zn chelation of MMPs (can also be oral)

               • N-Acetylcysteine 5-10%: Ca / Zn chelation of MMPs

          o Oral / parenteral antibiotics

               • Penetration of drug into tear film, cornea, and anterior chamber unknown

               • Corneal neovascularization and inflammation may increase drug delivery

               • TMS, Potassium Penicillin, Gentamicin

               • Doxycycline –

                    √ Antibiotic

                    √ Anti-inflammatory

                    √ Anticollagenolytic

                    √ Studies:

                         • Healthy @ 10 mg/kg BID x 5 days – drug not found

                         • Healthy @ 20 mg/kg BID x 5 days – drug found intraocular

                         • Healthy @ 20 mg/kg QD x 5 days – drug found in tears

          o Subconjunctival antibiotic / mydriatic – not ideal

               • Incited inflammatory response

               • Limited space

               • Unpredictable drug bioavailability as often need 2-3 times daily tx to achieve topical levels

     • Surgical TX: Utilize when medical tx delayed or ineffective

          o Provides:

               • Immediate vascular supply

                    √ Growth factors

                    √ Fibroblasts

                    √ Protease inhibitors

               • Structural support

          o Indications:

               • Ulcers with ≥ 50% stromal loss

               • Ulcers with ≤ 50% stromal loss but associated with progressing malacia

               • Descemetocele

               • Corneal perforation / iris prolapse

               • Monitor level of uveitis

          o Procedures:

               • Conjunctival grafts (pedicle, bipedicle, hood, free island, bridge, 360°)

               • Lamellar corneal grafts (corneoscleral or corneoconjunctival transposition)

               • Natural (amnion, autologous cornea) or synthetic/biosynthetic tissue (A-Cell, Biosys) grafts

          o After sx, medical tx should continue as previously administered

     • Prognosis: Variable!

          o Must control infection, corneal digestion, and associated inflammation

          o Different studies found 50-76% rate of visual success with a comfortable eye

Fungal ulcerative keratitis

     • Prevalence:

          o Regionally frequent (warm months, humid climates)

          o Regional species variability – need for culture / ID

     • Clinical Appearance:

          o Superficial keratomycosis

               • Microerosion

                    √ Multifocal subepithelial whitish opacities

                    √ Rose bengal positive +/- ulceration

                         • Epithelial devitalization

                    √ Pain, secondary uveitis variable

               • Superficial ulceration

                    √ More severe presentation

                    √ Defined epithelial loss with white / yellow cellular infiltration

                    √ Pain, secondary uveitis, neovascularization variable

               • Plaque formation ("cake-frosting" appearance)

                    √ Whitish-yellow necrotic plaque of stroma with ulceration

          o Stromal ulcerative keratomycosis – most common; 50-80% of cases with even more severe pain and anterior uveitis

               • Corneal furrowing

                    √ Curvilinear region of stromal loss @ ulcer edge

                    √ Rapidly occurs @ any time

               • Melting

               • Perforation

          o Stromal abscess

     • DDX: Cytology; cultures (bacterial / fungal); PCR?

          o Trauma / foreign bodies

          o Infiltrative ulcerative diseases

               • Bacterial

               • Eosinophilic

               • Herpesvirus

               • Immune-mediated

          o Mixed bacterial / fungal

               • 20-35% of infectious cases

          o Calcific band keratopathy

          o Corneal degeneration

          o Corneal neoplasia

     • Pathogenesis:

          o Loss of the epithelial barrier allows ocular surface and environmental fungal organisms to adhere, invade, and infect the stroma

          o Protease production by fungii, epithelial cells, inflammatory cells, and stromal fibroblasts results in extensive keratomalacia

          o Fungal organisms have been shown to inhibit in vitro angiogenesis

          o Deep stromal disease perpetuated by fungal affinity for the glycosaminoglycans near Descemet's membrane

          o Predisposing factors

               • Topical antibiotics

                    √ Healthy gram-positive microflora which produces balanced antifungal and antibacterial substances shifts to gram-negative in corneal ulcers

                    √ Antibiotic use can exacerbate this use

               • Topical steroids

               • Not all factors understood

               • Studies

                    √ 1998 UF (Andrew S): Fungal cases - 82% received topical AB; 15.4% received topical steroid prior to referral

                    √ 2009 (Galan A): Fungal cases - 60% received topical AB; 20% received topical steroid prior to referral

     • Medical TX:

          o Target fungi, secondary bacterial infection, corneal digestion, secondary anterior uveitis, and ocular pain

          o Antifungal medications:

               • Most antifungal drugs = fungistatic because of an inability to achieve adequate concentrations in the presence of an intact corneal epithelium

                    √ Epithelial loss – increases drug concentration

                    √ High frequency administration – increases drug concentration

               • Aggressive frequency

                    √ Does this result in clinical deterioration?

                         • Intense inflammatory reaction

                    √ Potential weighed against primary disease

               • Therapeutic debridement

                    √ Increase drug penetration

                    √ Debulk organism

               • Three general antifungal classes

                    √ Polyenes:

                         • Preferentially bind ergosterol, cell membrane sterol unique to fungi

                         • Increases cell permeability and leakage; oxidative damage

                         • Able to bind to cholesterol, mammalian membrane sterol potentially creating toxicities

                         • Broad spectrum

                         • Best for ulcerative disease

                         • Good efficacy against filamentous and yeast fungi

                         • Frequency: q 2-4 hrs initially, then taper

                         • Amphotericin B:

                              o Topical 0.075 – 0.2% solution in sterile water; refrigerate, dark bottle

                              o Increased epithelial toxicity vs Natamycin

                              o Subconjunctival – 0.2 mL of 5 mg / mL solution q 48 hrs for 3 doses

                         • Natamycin:

                              o 5% suspension

                              o Only commercial ophthalmic antifungal

                    √ Azoles:

                         • Preferentially binds to fungal specific enzyme in the cytochrome P450 system

                         • Inhibits ergosterol synthesis, increases membrane permeability, alters fungal cell enzyme systems

                         • Frequency: q 2-4 hrs initially, then taper

                         • Imidazoles

                              o Ketoconazole: 1%

                                   • Best for ulcerative disease

                                   • Poorer efficacy than other azoles

                              o Miconazole:

                                   • Topical 1%

                                   • Good penetration through intact epithelium

                                   • Subconjunctival 1% - 5 to 10 mg q 24 to 48 hrs

                         • Triazoles

                              o Fluconazole:

                                   • Topical 0.2% solution

                                   • Poorer efficacy vs other azoles against filamentous and yeast organisms

                                   • Systemic = 14 mg / kg PO once, then 5 mg / kg PO q 24 hrs

                                   • Good intraocular penetration with or without inflammation

                                   • More limited spectrum than other azoles

                              o Itraconazole:

                                   • Topical 1% in 30% DMSO suspension

                                   • Good penetration through intact epithelium

                                   • Systemic = 1.5 mg / kg IV q 24 hrs; 5.0 mg / kg PO q 24 hrs

                                   • Poor intraocular penetration

                                   • If using PO, use IV solution since capsules have highly variable absorption

                              o Voriconazole:

                                   • Topical 1% solution in sterile water

                                   • Refrigerate

                                   • Good penetration through intact epithelium

                                   • Systemic = 3 mg / kg PO q 12 hrs

                                   • Good intraocular penetration with or without inflammation

                                   • More limited spectrum than other azoles

                    √ Nucleoside analogs:

                         • Nucleoside analog, flucytosine, is enzymatically altered within the fungal cell to the cytotoxic principal fluorouracil

               • Others

                    √ Silver sulfadiazine

                         • 1% ointment

                         • Frequency: q 12-24 hrs

                         • Metal ions bind microbial DNA and inhibit synthesis

                    √ Povidone – iodine

                         • 2% solution

                         • Frequency: q 24 hrs

                         • Germicide

          o Topical antibiotics:

               • Targeted ideal

               • Prophylactic if primary organism not identified

          o Topical mydriatic – cycloplegic: see above (bacterial keratitis)

          o Systemic NSAIDs: see above (bacterial keratitis)

          o Systemic steroids: see above (bacterial keratitis)

          o Omeprazole (Gastrogard): see above (bacterial keratitis)

          o Topical antiproteases: see above (bacterial keratitis) –

          o Oral / parenteral antibiotics: see above (bacterial keratitis)

          o Subconjunctival antibiotic / mydriatic: see above (bacterial keratitis)

     • Surgical TX: Utilize when medical tx delayed or ineffective

          o Goals:

               • Remove infectious organisms and inflammatory cells

               • Immediate vascular supply

                    √ Growth factors

                    √ Fibroblasts

                    √ Protease inhibitors

               • Structural support

          o Indications:

               • Ulcers with ≥ 50% stromal loss

               • Ulcers with ≤ 50% stromal loss but associated with progressing malacia

               • Descemetocele

               • Corneal perforation / iris prolapse

               • Monitor level of uveitis

          o Procedures:

               • Conjunctival grafts (pedicle, bipedicle, hood, free island, bridge, 360°)

               • Lamellar corneal grafts (corneoscleral or corneoconjunctival transposition; posterior lamellar (PLK) or deep lamellar endothelial keratoplasty (DLEK), penetrating keratoplasty) +/- conjunctival grafting

               • Natural (amnion, autologous cornea) or synthetic/biosynthetic tissue (A-Cell, Biosys) grafts

          o After sx, medical tx should continue as previously administered

     • Prognosis: Variable!

          o Must control infection, corneal digestion, and associated inflammation

          o Treatment often very prolonged / costly

               • Range – 21 to 190 days

          o Globe retention: 70-95%

               • Visual: 50-90%

Questions

Related Content:

Ophthalmology
UC Davis study on eye diseases in kittens
UC Davis study on eye diseases in kittens
American College of Veterinary Ophthalmologists to offer service and working animals free eye exams
American College of Veterinary Ophthalmologists to offer service and working animals free eye exams
Senior penguins receive revolutionary cataract surgery
Senior penguins receive revolutionary cataract surgery

Advertisement

Latest News

Xylazine moves from the stables to the streets

DEA reports widespread threat of fentanyl mixed with xylazine

3 Must-reads for National Poison Prevention Week

UC Davis study on eye diseases in kittens

View More Latest News
Advertisement